SPARC licences development, commercialisation rights of PDP-716, SDN-037 to Visiox Pharma
The company will receive equity in Visiox along with other financial considerations
Sun Pharma Advanced Research Company (SPARC) has entered into an agreement with Visiox Pharma (Visiox) to grant exclusive worldwide rights (except for India and Greater China) for the development and commercialisation of PDP-716 and SDN-037.
Under the terms of the license agreement, SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10 per cent equity in Visiox.
“We are excited to enter into this collaboration. The collaboration with Visiox allows us to make PDP-716 and SDN-037 available to patients seeking to overcome the challenges associated with the currently marketed formulations of these drugs,” said Anil Raghavan, CEO, SPARC.
Michael Derby, Chairman, Visiox, said, “We are excited to partner with SPARC to register these important products and commercially launch them so that patients may be able to benefit from them as soon as possible. In Visiox, we look forward to building one of the industry’s leading ophthalmics companies.”
